The Research For Relation Between Excessive Delivery Of HSP70,HSP90 And Colon Rectal Cancer Shifting To Liver

colorectal cancer is a most common clinical type of tumor and liver is the most frequent transferred body part of this cancer. After this cancer shifting to the liver, its curative effect will be less optimistic ,and natural survival period will be short. If it is removed ,the prognosis will be improved. In recent years, by application of Oxaliplatin combined with 5-FU,and two-week scheme of FOLFOX4 ,the curative effect of this disease has been affirmed. Radiochemical treatment before operation can dwindle,capitulate the tumor and then enable some of the patients to regain the opportunity of curation after operation. This research probes into the relationship between the delivery level of HSP70> HSPH90 and the curative effect of radiochemical treatment of colorectal cancer transferring to liver, and does some exploration for the choice of radiochemical treatment drugs before operation and the judgement of the curative effect.Method: trailing and researching the 52 cases in which the primary affection focus of colorectal cancer has been removed,but liver-shift focus has not,and radiomedical treatment scheme of FOLFOX₄ has been kept up; adopting the method of close immunity histochemistry to measurate the delivery of HSP70å’ŒHSP90; applying CT to examine and compare the changes of the number and size of the focus before and after radiomedical treatment of the patients suffering colorectal cancer shifting to liver; through statistics,analyzing the relativity between the excessive delivery of HSP70 ft HSP90 and the curative effect of radiomedical treatment.Results: [1] Excessive delivery of HSP70å’ŒHSP90 has no relation to the patient's sex and different periods of TNM, but that of HSP70 shows correlation to patients' age--- positive sufferers of excessive delivery are relatively young and show distinct differences comparing with the negative sufferers. Meanwhile ,positive sufferers of excessive delivery of HSP90 have less ability to split tumor and show notable difference with negative sufferers. Excessive delivery of HSP70å’ŒHSP90 has no connection with serum tumor symbols and tumor immunity group delivery.[2] FOLFOX4 has a relatively affirmative effect in treatment of colorectal cancer shifting to liver. After three months of radiomecical treatment ,of the 52 sufferers, the tumor of 28 has been reduced by over 50%, the rate of PR is 53.8%. Only 8 cases have been worsened ,and the rate of PD is 15.4%.[3] Between sufferers of excessive delivery of HSP70 and those of non-excessive delivery of HSP70 exists a great difference in the curative effect in the application of radiomedical treatment scheme of FOLFOX4 to treat colorectal cancer shifting to liver. For the patients of positiv excessive delivery of HSP70 ,the rate of PR is 42.9%, while for the negative, 61.3%. But obvious difference of curative effect of radiomedical treatment has not been found in the difference of delivery degree of HSP90.[4] Before radiomedical treatment, the delivery of the serum tumor symbols(CEA,CA19-9,CA125,AFP,CA15-3)has no pertinency with curative effect of radiomedical treatment. The delivery of the original tissues(CEA,CA19-9,P53,Ki67) of colorectal cancer is not related to curative effect of radiomedical treatment of liver-shifting focus.Conclusion:1,Before radiomedical treatment, the delivery of the serum tumor symbols(CEA,CA19-9,CA125,AFP,CA15-3)has no pertinency with curative effect of radiomedical treatment. The delivery of the original tissues(CEA,CA19-9,P53,Ki67) of colorectal cancer is not related to curative effect of radiomedical treatment of liver-shifting focus.2,The patients of excessive delivery of HSP90 are less able to split tumor tissues. The curative effect on sufferers of excessive delivery of HSP70 is relatively pessimistic.